

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: <b>Alan Solomon <i>et al.</i></b>	)	Confirmation No. <b>3133</b>
	)	
Application No. <b>09/825,872</b>	)	Group Art Unit: <b>1656</b>
	)	
Filed: <b>April 5, 2001</b>	)	Examiner: <b>Chih Min Kam, Ph.D.</b>
	)	
For: <b>Methods of Investigating, Diagnosing and Treating Amyloidosis</b>	)	Date: <b>November 25, 2008</b>
	)	

**COMMENTS ON STATEMENT OF REASONS FOR ALLOWANCE**

In response to the Examiner's Statement of Reasons for Allowance in the Notice of Allowability dated August 25, 2008, the following comments are submitted under 37 C.F.R. 1.104(e).

While Applicants believe that the claims are allowable and patentably distinguishable over the cited art, Applicants do not acquiesce that the cited art disclose compositions suitable for *in vivo* administration, such as compositions suitable for pharmaceutical administration or vaccination. Applicants have canceled claims to such compositions in this application solely for the purpose of expediting prosecution.

Dated: **November 25, 2008**  
Morgan, Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
202-739-3000

Respectfully submitted,  
**Morgan, Lewis & Bockius LLP**

/Sally Teng/

---

Sally P. Teng  
Registration No. 45,397